Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Plasma cell 1Gastrointestinal 1CNS 1

Conditions

Melanoma 36Carcinoma, Renal Cell 16Prostatic Neoplasms 10Neoplasm Metastasis 10Leukemia, Myeloid, Acute 9Carcinoma, Non-Small-Cell Lung 9Uveal Melanoma 8Myelodysplastic Syndromes 8Leukemia, Lymphocytic, Chronic, B-Cell 7Clear-cell metastatic renal cell carcinoma 7Lymphoma, Non-Hodgkin 6Lung Neoplasms 6Hematologic Neoplasms 6Triple Negative Breast Neoplasms 5Sarcoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Ovarian Neoplasms 5Multiple Myeloma 5Hodgkin Disease 5Breast Neoplasms 5Brain Neoplasms 5Uterine Cervical Neoplasms 4Pancreatic Neoplasms 4Lymphoma, Follicular 4Histiocytoma, Malignant Fibrous 4Gastrointestinal Stromal Tumors 4Burkitt Lymphoma 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3

Interventions

Cyclophosphamide 447Rituximab 406Etoposide 225Vincristine 217Doxorubicin 204Filgrastim 201Prednisone 178Cytarabine 160Radiotherapy 152fludarabine phosphate 148Methotrexate 137Peripheral Blood Stem Cell Transplantation 130Melphalan 128fludarabine 116Busulfan 101Dexamethasone 93Tacrolimus 76Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 72Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 63Bendamustine Hydrochloride 63Lenalidomide 62Cyclosporine 62Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma × CTLA-4 Antigen × Clear all
NCT03502733 2026-05-13

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
64 enrolled
Lymphoid

Lymphoma, Neoplasm Metastasis

NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

NCT01919619 2024-12-03

Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

M.D. Anderson Cancer Center

Phase 2 Completed
41 enrolled 11 charts
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡